296 related articles for article (PubMed ID: 31279295)
1. Natural products against renin-angiotensin system for antifibrosis therapy.
Yang T; Chen YY; Liu JR; Zhao H; Vaziri ND; Guo Y; Zhao YY
Eur J Med Chem; 2019 Oct; 179():623-633. PubMed ID: 31279295
[TBL] [Abstract][Full Text] [Related]
2. Blockade of renin-angiotensin system in antifibrotic therapy.
Yoshiji H; Kuriyama S; Fukui H
J Gastroenterol Hepatol; 2007 Jun; 22 Suppl 1():S93-5. PubMed ID: 17567477
[TBL] [Abstract][Full Text] [Related]
3. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.
Burchill LJ; Velkoska E; Dean RG; Griggs K; Patel SK; Burrell LM
Clin Sci (Lond); 2012 Dec; 123(11):649-58. PubMed ID: 22715807
[TBL] [Abstract][Full Text] [Related]
4. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
5. Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?
Garg M; Royce SG; Tikellis C; Shallue C; Batu D; Velkoska E; Burrell LM; Patel SK; Beswick L; Jackson A; Britto K; Lukies M; Sluka P; Wardan H; Hirokawa Y; Tan CW; Faux M; Burgess AW; Hosking P; Monagle S; Thomas M; Gibson PR; Lubel J
Gut; 2020 May; 69(5):841-851. PubMed ID: 31409604
[TBL] [Abstract][Full Text] [Related]
6. Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension.
Shim KY; Eom YW; Kim MY; Kang SH; Baik SK
Korean J Intern Med; 2018 May; 33(3):453-461. PubMed ID: 29462546
[TBL] [Abstract][Full Text] [Related]
7. Development of inhibitors of the aspartyl protease renin for the treatment of hypertension.
Scott BB; McGeehan GM; Harrison RK
Curr Protein Pept Sci; 2006 Jun; 7(3):241-54. PubMed ID: 16787263
[TBL] [Abstract][Full Text] [Related]
8. Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options.
Grace JA; Herath CB; Mak KY; Burrell LM; Angus PW
Clin Sci (Lond); 2012 Aug; 123(4):225-39. PubMed ID: 22548407
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation.
Fukuda D; Enomoto S; Nagai R; Sata M
Biomed Pharmacother; 2009 Dec; 63(10):754-61. PubMed ID: 19304450
[TBL] [Abstract][Full Text] [Related]
10. [The future of renin inhibition].
Uresin AY; Baran E
Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
[TBL] [Abstract][Full Text] [Related]
11. Effects of direct renin inhibition versus angiotensin II receptor blockade on angiotensin profiles in non-diabetic chronic kidney disease.
Antlanger M; Bernhofer S; Kovarik JJ; Kopecky C; Kaltenecker CC; Domenig O; Poglitsch M; Säemann MD
Ann Med; 2017 Sep; 49(6):525-533. PubMed ID: 28358246
[TBL] [Abstract][Full Text] [Related]
12. Recent changes in the landscape of combination RAS blockade.
Epstein BJ; Smith SM; Choksi R
Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
[TBL] [Abstract][Full Text] [Related]
13. Fiend and friend in the renin angiotensin system: An insight on acute kidney injury.
Sharma N; Anders HJ; Gaikwad AB
Biomed Pharmacother; 2019 Feb; 110():764-774. PubMed ID: 30554115
[TBL] [Abstract][Full Text] [Related]
14. Dual blockade of the renin-angiotensin-aldosterone system with high-dose angiotensin-converting enzyme inhibitor for nephroprotection: an open, controlled, randomized study.
Tylicki L; Renke M; Rutkowski P; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Scand J Urol Nephrol; 2008; 42(4):381-8. PubMed ID: 19230172
[TBL] [Abstract][Full Text] [Related]
15. Update on New Aspects of the Renin-Angiotensin System in Hepatic Fibrosis and Portal Hypertension: Implications for Novel Therapeutic Options.
Rajapaksha IG; Gunarathne LS; Angus PW; Herath CB
J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33670126
[TBL] [Abstract][Full Text] [Related]
16. Blocking the renin-angiotensin system: dual- versus mono-therapy.
Ravandi A; Teo KK
Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
[TBL] [Abstract][Full Text] [Related]
17. Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure.
Arendse LB; Danser AHJ; Poglitsch M; Touyz RM; Burnett JC; Llorens-Cortes C; Ehlers MR; Sturrock ED
Pharmacol Rev; 2019 Oct; 71(4):539-570. PubMed ID: 31537750
[TBL] [Abstract][Full Text] [Related]
18. Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary diseases.
Tan WSD; Liao W; Zhou S; Mei D; Wong WF
Curr Opin Pharmacol; 2018 Jun; 40():9-17. PubMed ID: 29288933
[TBL] [Abstract][Full Text] [Related]
19. Role of the RAS in pancreatic cancer.
Lau ST; Leung PS
Curr Cancer Drug Targets; 2011 May; 11(4):412-20. PubMed ID: 21395550
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of renin: an updated review of the development of renin inhibitors.
Li YC
Curr Opin Investig Drugs; 2007 Sep; 8(9):750-7. PubMed ID: 17729187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
